Market Value 💰💰💰 We could look at current revenues, revenues of Penta5, and projected revenues once the acquisition is complete. First I’d consider looking at current valuation with current fundamentals. I would argue that, as is, there is a discrepancy in market valuation of PREV, all things considered, not including the Penta5 acquisition. 39 million for a company that has market ready products in the preventative health market, along with high level academic R&D, and a pipeline of market disruptive technologies and medicines; is arguably undervalued. Then I would consider the projected 400 million in revenue of Penta5, and how that will reflect on PREV’s market valuation going forward. Once you’ve done that; think product and packaging patents, international licensing agreements, indefinite royalties. The list goes on. Hard to quantify? I agree.